Human Papillomavirus (HPV) Antibodies from GeneTex

Human papillomaviruses (HPV), transmitted largely through sexual contact, cause almost 700,000 cases of cancer (primarily of the cervix) per year worldwide (1, 2). Perhaps a dozen of the more than 200 HPV types are considered oncogenic, with HPV16 and HPV18 alone responsible for ~50-70% of cervical cancers as well as multiple HPV-associated, non-cervical neoplasms (which include oropharyngeal, vulvar, vaginal, anal, and penile cancers) (2). The viral oncoproteins E6 and E7 are the key proteins driving carcinogenesis through their actions on growth regulatory pathways (1). Vaccines offer highly efficacious and long-lasting protection from the development of HPV-attributable malignancies, and the World Health Organization (WHO) has advocated for increased HPV awareness and efforts to expand international vaccination, screening, and treatment initiatives (2, 3-5).

GeneTex hopes to support HPV research through the production of high-quality antibodies, including several that are fully recombinant, targeting the oncoproteins of HPV16 and HPV18. To learn more, please see the product images below and review the GeneTex catalog of HPV-related reagents.

 

Highlighted Products

 

HPV16-specific

 

HPV16 E7 antibody [HL1647] GTX637228	Capture: HPV16 E7 antibody [HL1647] (GTX637228) Detection: HPV16 E7 antibody [HL1821] (GTX637546)

 

HPV18-specific

 

HPV18 E7 antibody [GT881] GTX634337	HPV18 E7 antibody [GT881] GTX634337

 

 

References:

1. Nat Rev Dis Primers. 2016 Dec 1;2:16086. doi: 10.1038/nrdp.2016.86.
2. N Engl J Med. 2023; 388:1790-1798 doi: 10.1056/NEJMcp2108502.
3. World Health Organization. Cervical cancer.
4. World Health Organization. WHO Director-General calls for all countries to take action to help end the suffering caused by cervical cancer.
5. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem.